Navigation Links
Orphan Drugs in Oncology Drug Pipeline Update 2013
Date:11/19/2013

London (PRWEB) November 19, 2013

This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to promote the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases. This designation will in many countries provide several years of marketing exclusivity if the product candidate is approved for the designated orphan indication. It also provides special incentives for sponsors, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of applying for marketing approval.

There are today 303 companies plus partners developing 400 orphan drugs in oncology drugs in 2245 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 119 drugs. Orphan Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 290 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 281 out of the 283 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 66 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

*Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Drug Pipeline Update at a Glance

Investigators
Includes more than 303 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms
Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 400 orphan drugs in oncology drugs in development, which have a total of 2245 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 127
Pre-registration# 16
Phase III# 122
Phase II# 265
Phase I# 174
Preclinical# 72
No Data# 15
Suspended# 11
Ceased# 119

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

Included orphan drugs in oncology drugs are also in development for 334 other indications, where of 132 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets
Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 281 out of the 283 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 208 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4117 structures available today among drug targets.

Identified drugs are linked to more than 290 different targets, divided into 66 classifications of molecular function:
-Aminopeptidase activity
-ATPase activity
-Auxiliary transport protein activity
-Carboxy-lyase activity
-Catalytic activity
-Cell adhesion molecule activity
-Chaperone activity
-Chemokine activity
-Complement activity
-Cysteine-type peptidase activity
-Cytokine activity
-Deacetylase activity
-Deaminase activity
-DNA binding
-DNA repair protein
-DNA topoisomerase activity
-DNA-directed DNA polymerase activity
-DNA-methyltransferase activity
-Extracellular ligand-gated ion channel activity
-Extracellular matrix structural constituent
-Fucosyltransferase activity
-G-protein coupled receptor activity
-Growth factor activity
-GTPase activity
-Hydrolase activity
-Isomerase activity
-Kinase activity
-Kinase binding
-Kinase regulator activity
-Ligand-dependent nuclear receptor activity
-Ligase activity
-Lipid kinase activity
-Lipid phosphatase activity
-Metallopeptidase activity
-MHC class I receptor activity
-Molecular function unknown
-Oxidoreductase activity
-Peptide hormone
-Peroxidase activity
-Phosphoric diester hydrolase activity
-Phosphorylase activity
-Protease inhibitor activity
-Protein binding
-Protein serine/threonine kinase activity
-Protein threonine/tyrosine kinase activity
-Protein tyrosine phosphatase activity
-Protein tyrosine/serine/threonine phosphatase activity
-Protein-tyrosine kinase activity
-Receptor activity
-Receptor binding
-Receptor signaling complex scaffold activity
-Receptor signaling protein serine/threonine kinase activity
-RNA binding
-RNA-directed DNA polymerase activity
-Serine-type peptidase activity
-Structural constituent of cytoskeleton
-Superoxide dismutase activity
-T cell receptor activity
-Transcription factor activity
-Transcription regulator activity
-Transferase activity
-Translation regulator activity
-Transmembrane receptor activity
-Transmembrane receptor protein tyrosine kinase activity
-Transporter activity
-Voltage-gated ion channel activity

Sub-Cellular Localization
Identified targets are categorized into 27 different primary and alternate sub-cellular localizations:
-Cell surface
-Centrosome
-Clathrin-coated vesicle
-Cytoplasm
-Cytoplasmic vesicle
-Cytoskeleton
-Cytosol
-Endoplasmic reticulum
-Endosome
-Extracellular
-Golgi apparatus
-Integral to membrane
-Kinetochore
-Lysosome
-Microtubule
-Mitochondrial membrane
-Mitochondrion
-Nuclear membrane
-Nucleolus
-Nucleus
-Perinuclear region
-Perinuclear vesicle
-Plasma membrane
-Sarcoplasmic reticulum
-Secreted
-Secretory granule
-Secretory vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile
Direct links are provided from inside the application to 387 protein expression profiles of 248 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
-48 different normal tissue types
-20 different types of cancer
-47 cell lines
-12 samples of primary blood cells

Pathway Referals
Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
-BioCarta# 245 Pathways
-KEGG# 190 Pathways
-NCI-Nature# 244 Pathways
-NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism
In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound
Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & Synonyms
Presentation of drug name and synonyms

Principal Company & Partners
Presentation of principal company and partners

Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function

Target Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells

Mutation
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.

Biological Structures
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism
Drug mechanism of action

Developmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased

Drug Description
Short introduction to drug

Compound Data
Compound type, Chemical name, CAS Number and molecular weight

Patent Data
Available patent information related to the drug is presented here.

Fillings and Approvals
Approvals and submissions
Analyst comments

Deals & Licensing
Collaborations and deals
Availability for licensing

Phase IV Data
Available Phase IV development data, developmental history and scientific data.

Phase III Data
Available Phase III development data, developmental history and scientific data.

Phase II Data
Available Phase II development data, developmental history and scientific data.

Phase I Data
Available Phase I development data, developmental history and scientific data.

Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.

Preclinical Data
Available preclinical development data, developmental history and scientific data.

Discovery Data
Available discovery development data, developmental history and scientific data.

Application Features
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.

Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.

Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
-Drug data is linked to search engines like Google and PubMed
-Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
-Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

Click here for a short video (6m12s) showing a typical drug profile.

System Requirements
-Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
-Browser Application (Internet Explorer)
-Internet access (to access related internet resources)

Read the full report:

Orphan Drugs in Oncology Drug Pipeline Update 2013

http://www.reportbuyer.com/pharma_healthcare/therapeutic/orphan_drugs_oncology_drug_pipeline_update_2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11348764.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DIA-NORD Conference on Rare Diseases and Orphan Products to Feature Patients Discussing Challenges to Diagnosis and Treatment
2. Early Registration Deadline on Monday for U.S. Conference on Rare Diseases and Orphan Products
3. AED.com and Rescue Heart Foundation Donate AED to Haitian Orphanage
4. Orphan Drugs Market Partnering Deals and Agreements by Healthcare Companies Reviewed in New Research Report at RnRMarketResearch.com
5. Georgia Partnership for TeleHealth and LSU Partner to Bring Telemedicine to Orphanage in Guatemala
6. Orphan Drug Market to Reach $112 Billion in 2017: Bcc Research
7. Ground Broken For New Orphanage In Africa Thanks To Living Fuel And FreeRide836 Kiteboarders
8. Tellurex Sends tPOD1™ to Light Up Orphanage in Uganda
9. FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa
10. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
11. First Pathfinder Awards announced tackling rare and orphan diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... 2016 , ... A national ergonomics pioneer , HealthPostures, ... March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo will ... running and largest worker's compensation event in Ohio, organizers of the safety congress ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has ... readily available to physicians. The integration will enable Allscripts users to post ... via Everseat’s free mobile app. , The partnership gives Everseat substantial added power ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional Divisions - ... - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social Media: ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Workrite ... based company that has evolved from humble beginnings to being an internationally recognized leader ... company that we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 10, 2016 CSI Specialty Group (CSI) ... launch of the Specialty Pharmacy Podcast. A free, weekly ... at providing real-world education, discussion and context amongst specialty ... --> The Specialty Pharmacy Podcast, ... CSI Specialty Group Suzette DiMascio, CHE, CMCE, CPC, is ...
(Date:2/10/2016)... MINNEAPOLIS , Feb. 10, 2016 Urologix, ... for the treatment of Benign Prostatic Hyperplasia (BPH), announces ... Ash Keswani , a medical device industry veteran ... of the Limited Liability Company.  ... and service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, ...
(Date:2/10/2016)... Feb. 10, 2016  Oxis International Inc. (OTC/QB: OXIS) ... was described as a "clinical trial triumph" after one ... into complete cancer remission. Daniel Vallera ... Masonic Cancer Center. --> Daniel Vallera ... Masonic Cancer Center. --> An article ...
Breaking Medicine Technology: